A B S T R A C T In this paper we show that the ferrochelatase defect in erythropoietic protoporphyria (EPP) can readily be identified in mitogen-stimulated lymphocytes since such cells from patients with EPP accumulate approximately twice as much protoporphyrin IX as cells from normal subjects when incubated with a porphyrin precursor, 6-aminolevulinic acid (ALA). Treatment of cultures with ALA and with the iron chelator, CaMgEDTA significantly increased the level of protoporphyrin IX in mitogen-stimulated lymphocytes from normal subjects, while the same treatment failed to produce an increase in protoporphyrin IX in cell preparations from EPP patients. In contrast to the results with the chelator treatment, supplementation of the cultures with iron and ALA reduced the level of protoporphyrin IX in normal cells, but not in EPP cells. These findings are compatible with a partial deficiency of ferrochelatase in EPP lymphocytes. The gene defects of acute intermittent porphyria and hereditary coproporphyria have previously been identified using lymphocyte preparations from the gene carriers of these diseases. The present study demonstrates that EPP represents another form of human porphyria in which the gene defect of the disease can now be identified in lymphocyte preparations.
INTRODUCTION
Erythropoietic protoporphyria (EPP)' is an inherited disorder of porphyrin metabolism characterized clin-ically by photosensitivity and biochemically by marked increases of protoporphyrin IX in erythroid cells, plasma, and feces. In humans EPP is inherited as an autosomal dominant disease with a variable degree of penetrance. This is in contrast to the only other major form of erythropoietic porphyria in man, congenital erythropoietic porphyria (Guinther's disease), which is an autosomal recessive disease. However an autosomal recessive form of EPP has recently been described in cattle (1) . Previous studies have demonstrated that the activity of ferrochelatase, the last enzyme in the heme biosynthetic pathway, is deficient in a number of tissues and isolated cell preparations from EPP patients, including bone marrow (2), nucleated peripheral blood cells (3) , liver (4) , and cultured skin fibroblasts (4) . A deficiency of ferrochelatase activity would be consistent with the marked increases in protoporphyrin IX found in EPP, since this porphyrin is a substrate for this enzyme.
We have reported earlier the usefulness of a method employing mitogen-stimulated lymphocyte cultures for detecting gene carriers of acute intermittent porphyria (AIP) in which there is a 50% deficiency of porphobilinogen (PBG) deaminase activity (5) . In this method 6-aminolevulinic acid (ALA) added to lymphocytes is metabolized to protoporphyrin IX, which accumulates and is readily measured in such cells. When incubated with ALA, mitogen-stimulated lymphocytes from AIP subjects accumulated '50% less protoporphyrin IX than did cells from normal subjects. This was found to reflect a 50% deficiency of PBG deaminase in these cells of Subjects studied. Nine patients with EPP ranging in age from 12-46 yr (six clinically affected males, and three clinically affected females) and eight normal subjects ranging in age from 18 to 56 yr (five males and three females) were studied. The clinically affected EPP subjects all had moderate to marked skin photosensitivity and marked increases of protoporphyrin IX in their erythrocytes and plasma. In addition, three clinically latent females had mild, but significantly elevated, levels of protoporphyrin IX in their erythrocytes and plasma; one was the mother and two others were the sisters of the three affected EPP patients.
Cell cultures. Mononuclear cell concentrates were prepared from defibrinated blood by isopyknic sedimentation using Ficoll-metrizoate solution as described previously (5) . Contaminating erythrocytes were eliminated by hemolysis with NH4Cl-KHCO3 (5, 7) . Cells were then suspended in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin 100 Mg/ml, streptomycin 100 ,g/ml, and 1% (wt/vol) PHA, and 1% (wt/vol) PWM.
The final cell concentration was adjusted to 5 X 105 cells/ ml with the medium. Cell counting was performed using a Cytograf 6300A (Ortho Instruments, Inc., Raritan, NJ). Approximately 2-2.5 X 107 mononuclear cells were usually obtained from 50 ml of peripheral blood. Differential counts from smears of final cell preparations showed 2 granulocytes and 10 erythrocytes per 1,000 nucleated cells. 1 ml of this cell suspension was then transferred to a 12 X 100-mm Falcon plastic tube and incubated at 37°C for 72 h in an atmosphere of 5% CO2 and 100% humidity.
Assays. After incubation with mitogens for 72 h, the cells were centrifuged and then washed with 1 ml of serum-free modified F12 medium supplemented with bovine crystalline insulin (1 Mg/ml). This insulin-containing medium (termed "F-I"), was found previously to be useful in the quantitation of porphyrins in chick embryo hepatocytes (7), in human and bovine skin fibroblasts (6, 8) , and in mitogen-stimulated human lymphocytes (5 (7, 8) .
After incubation with ALA for 24 h, cells were harvested by centrifugation at 600 g for 5 min. Porphyrin was extracted from cell pellets with 500,l of a mixture of equal volumes of 1 N perchloric acid and methanol. After centrifugation at 600 g for 5 min the supernatant was transferred to a 6 X 50-mm glass test tube (Kimble, Owens-Illinois, Inc. Toredo, OH) for porphyrin fluorescence assay. A fluorescence emission spectrum of the extract was obtained in these tubes using a Hitachi-Perkin Elmer model 4 fluorescence spectrophotometer (Perkin-Elmer Corp., Mountain View, CA) equipped with a semimicro-cell holder (8) and a red sensitive photomultiplier R-928. Coproporphyrin (0.1 uM) in 0.14 N HCI was used as a standard for calibrating the spectrofluorometer. After the perchloric acid-methanol extraction, the cellular precipitate was dissolved in 400 ,ul 0.2 N NaOH with heating at 60°C for 30 min and protein concentration was determined by the method of Lowry et al. (9) . PBG deaminase activity was assayed in 0.5 X 106 cells be a semimicrofluorometric method as described previously (5).
RESULTS
In both normal and EPP lymphocytes incubated after treatment with PHA and PWM, porphyrin accumulation from the added ALA increased as a function of incubation time as shown in Fig. 1 (Fig. 1) . Spectrofluorometric analysis of porphyrins formed by lymphocyte cultures indicated that essentially all porphyrins formed were of the protoporphyrin IX type in both normal and EPP lymphocytes. Porphyrin accumulation was greatest when both 0.5-1% PHA and 1% PWM were added, and with cell densities in the range of 0.1 to 1.0 X 106 cells/ml. In both normal and EPP lymphocytes we found that protoporphyrin IX accumulation after a 3-d preincubation with mitogens was 10-15-fold greater than in cells from the same subjects that were not incubated with the mitogens.
Protoporphyrin IX accumulation was also proportional to ALA concentration (Fig. 2) mulation from ALA in EPP lymphocytes was thus approximately twofold greater than that observed in normal lymphocytes. This finding strongly suggests that ferrochelatase activity in lymphocytes from patients with EPP as determined in the intact cell is functionally deficient and is only -50% that of normal cells. Similar findings of excess protoporphyrin IX accumulation from added ALA have been reported in skin fibroblast cultures from patients with EPP (10) and from cattle with an autosomal recessive form of EPP (6) . Our previous studies have shown that the iron chelator CaMgEDTA is an inhibitor of ferrochelatase in cultured chick embryo hepatocytes (7), chick embryo dorsal root ganglion cells (11, 12) , and bovine skin fibroblasts (6). We therefore examined the effect of CaMgEDTA on protoporphyrin IX accumulation in mitogen-stimulated lymphocytes from EPP patients and normal subjects. Protoporphyrin IX accumulation in normal lymphocytes stimulated with mitogens was increased by treatment with CaMgEDTA, by an average of 2.4-fold, whereas the average increase produced by CaMgEDTA in EPP lymphocytes was only 1.7-fold (Fig. 3B) . Differences in protoporphyrin IX accumulation between normals and EPP patients became less in the presence of CaMgEDTA than in the absence of CaMgEDTA. These findings suggest that less ferrochelatase is present and subject to inhibition by the chelator in EPP lymphocytes than in normal lymphocytes.
The effect of iron on protoporphyrin IX accumulation in mitogen-stimulated lymphocytes incubated with ALA is shown in Fig. 3C . When normal lymphocytes were incubated with iron and ALA, iron reduced the level of protoporphyrin IX accumulation by -30%, suggesting that heme formation from protoporphyrin IX is increased when more iron is available (Fig. SC) . A similar effect of added iron has been reported in cultured skin fibroblasts from EPP patients (10) . However, when EPP lymphocytes were treated with iron in addition to ALA there was no detectable difference in protoporphyrin IX concentrations (Fig.  3C) . These results suggest that the deficient ferrochelatase in the cells from EPP patients is already at its maximum activity and that heme formation cannot be further increased by a greater supply of iron.
We also studied lymphocytes from eight members of a single family (Table I) including three patients with clinically manifest EPP (cases 11-2, II-5, II-6) and five clinically unaffected subjects (cases I-1, I-2, II-1, II-3, 11-4) three of whom proved to be gene carriers of EPP (cases I-2, II-3, II-4). The three patients with clinically manifest EPP had long-standing cutaneous photosensitivity and markedly elevated protoporphyrin IX in their erythrocytes and plasma (Table I) . Accumulation of protoporphyrin IX from added ALA in lymphocytes from these patients was in the range of that for the other EPP patients we studied (Fig. 3) . Responses of the cell culture to CaMgEDTA and to iron were, as expected, lower in lymphocytes from the three patients than in cells from normal subjects. Lymphocyte preparations from the father (I-1) and a sister (II-1) accumulated normal amounts of protoporphyrin IX from exogenous ALA and the responses of their cells to treatment with CaMgEDTA or iron were also normal. Therefore, these two subjects clearly did not carry the EPP gene defect (Table I) . The mother (I-2) and two sisters (II-3, 11-4) were clinically unaffected; however, their plasma contained slightly elevated levels of protoporphyrin IX (Table I) . One sister (II-3) was not available for lymphocyte studies, but was also shown to have increased protoporphyrin IX in plasma. The mitogen-treated lymphocytes from the mother (I-2) and another sister (II-4) produced amounts of protoporphyrin IX from ALA that were intermediate between those accumulated in cells from normal subjects and by cells from the members of this family with clinically manifest EPP. Responses of cells from these two subjects (I-2, II-4) to CaMgEDTA or iron treatment were similar to those characterizing the clinically manifest EPP patients. The data from the lymphocyte studies of these two subjects thus clearly identify them as gene carriers of EPP; in view of the absence of an appropriate clinical history of EPP, both subjects can properly be defined as having clinically latent EPP.
DISCUSSION
The results of the present study demonstrate that a deficiency of ferrochelatase in EPP patients can be detected by incubating mitogen-stimulated lymphocytes with ALA and measuring the amount of protoporphyrin IX that accumulates in the cells. Lymphocytes from EPP patients accumulated approximately twice as much protoporphyrin IX from added ALA (15) (16) (17) affect the enzyme activity in vitro and these may bear on the very wide range (13.7-51.5 pmol protoheme/mg protein per h for normal fibroblasts and 60-580 pmol protoheme/mg protein per h for normal liver biopsy specimens) of ferrochelatase activities reported by Bonkowsky et al. (4) . Additionally, the enzyme is known to be quite unstable and to form intractable aggregates during purification (18) ; variations in its activity could therefore result from in vitro tissue manipulations. In the work we report here, the intact lymphocyte culture system obviated these potential difficulties of the in vitro ferrochelatase assay, and the data obtained indicate an -50% deficiency of ferrochelatase activity in EPP, which is consistent with the heterozygous status of these subjects for the gene defect of this disease.
Mailer et al. (18) have demonstrated that the ferrochelatase purified from rat liver mitochondria consists of a single polypeptide with a molecular weight of 63,000. Ferrochelatase from human sources has not to date been purified to homogeneity. Therefore it is not possible to conclude that the enzyme in EPP cells is structurally different from the normal enzyme, although this has been suggested (19) .
A pedigree study of an EPP family (Table I) disclosed that three male subjects were clinically affected EPP patients and that the mother and two of three sisters were latent gene carriers of the disease. In general, clinically expressed EPP affects both sexes equally with possibly a slight male preponderance (20, 21) and the exclusive male occurrence of clinically manifest EPP in this family is unusual. An important observation made from this family study is that lymphocytes, from the two clinically latent (i.e. without photosensitivity) gene carriers of EPP (cases 1-2, and 11-4 in Table I), whom it was possible to study in this fashion, showed intermediate levels of protoporphyrin IX accumulation in lymphocytes after ALA treatment, and their responses to CaMgEDTA or iron were clearly characteristic of clinically expressed EPP subjects. Moreover in the clinically latent subjects in this family, plasma protoporphyrin IX levels were slightly, but significantly, increased and their erythrocyte protoporphyrin IX levels were also greater than the levels of normal family members. Similar increases of protoporphyrin IX in erythrocytes have been reported to occur in latent EPP gene carriers by Reed et al. (20) . These findings suggest that there can be a difference in the extent of the functional ferrochelatase activity between clinically manifest EPP patients and clinically latent gene carriers of the disease. It is well established that human EPP is an autosomal dominant disorder with a variable degree of penetrance; thus EPP patients as well as latent gene carriers of the disease are presumably heterozygous for a single gene defect.-Our findings suggest that although a single gene mutation may explain the genetic defect in EPP, some additional factor(s) is probably required for full clinical expression of the gene lesion in this disorder. An analogous situation exists with respect to the dominant forms of the hepatic porphyrias such as AIP (22, 23) . However, the metabolic differences, i.e., those involving endocrine status (22, 23) that distinguish completely latent from clinically expressed gene carriers of AIP, do not alter the level of the PBG deaminase deficiency in this disorder (8, 13, 24) . In the case of EPP the nature of the factor(s) that influence the clinic-al expression of the gene defect of the disease is not known. In an experimental hepatic porphyria induced in mice and rats by treatment with 3,5-diethoxy-carbonyl-1,4-dihydrocollidine, a green porphyrin-like heme breakdown product that potently inhibits ferrochelatase activity is known to be produced in the liver (25) . In addition to the primary genetic deficiency of ferrochelatase in EPP, there may also be other factors which affect the activity of the enzyme and identification and characterization of such factors would clearly be important in understanding the mechanism of clinical expression of this disorder.
Finally, only 4 d are required for the technique described in this method, a time which is much shorter than that required for assays using cultured skin fibroblasts (6, 10, 26) . The lymphocyte culture system is thus considerably more convenient for detecting EPP gene carriers than the fibroblast system. The technique utilizing the incubation of cultured fibroblasts with ALA, ALA plus CaMgEDTA, and ALA plus iron has also been successful in identifying the gene defect in the recessively inherited bovine form of EPP (6) . In addition to cattle with clinically manifest EPP who are homozygous for the gene defect of the disease, heterozygous animals who are clinically latent could also be identified by this method.
